IRIS
BAGNASCO, DIEGO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.267
Totale 5.267
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 5.267
Totale 5.267
Salva come PNG Salva come JPEG
Città #
Genova 2.934
Genoa 825
Vado Ligure 751
Rapallo 724
Bordighera 33
Totale 5.267
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 170
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma 142
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 140
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 139
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 139
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 134
Personalized medicine in allergy 129
Current insights in allergen immunotherapy 124
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 124
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation 122
The safety of monoclonal antibodies in asthma 121
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation 121
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases 119
Biosimilars in allergic diseases 118
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis 116
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations 114
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma 113
Umeclidinium for the treatment of uncontrolled asthma 110
The path to personalized medicine in asthma 110
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? 108
Impact of tDCS on persistent COVID-19 olfactory dysfunction: a double-blind sham-controlled study 108
Multiple pulmonary nodules and unexplained fever: when the pulmonologist fails. 105
Update on immunotherapy for the treatment of asthma 101
Severe asthma, biologicals, and auto-injection: Yes, no, may be! 93
30 Years Of Sublingual Immunotherapy 92
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials 92
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment 91
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 91
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19 87
One year of mepolizumab. Efficacy and safety in real-life in Italy 84
Mepolizumab in severe asthma: evidence in real-life 83
The importance of being not significant: blood eosinophils and clinical responses do not correlate in severe asthma patients treated with Mepolizumab in real life 82
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies 81
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 81
Biologicals for severe asthma: what we can learn from real-life experiences? 80
Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy 78
Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study 71
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 69
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs 68
Evolving phenotypes to endotypes: is precision medicine achievable in asthma? 64
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity 58
Minimal clinically important difference for asthma endpoints: An expert consensus report 57
Biological agents for severe asthma: the evolution of the at-home self-injection approach. 56
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 56
Application of bioendoscopy filters in endoscopic assessment of sinonasal Schneiderian papillomas 53
FEV6 assessment in spirometric abnormalities screening: the first population-based study in Italian pharmacies 51
null 49
Anti-il5 therapies for severe eosinophilic asthma: Literature review and practical insights 47
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 47
Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies 36
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center 34
Severe asthma: One disease and multiple definitions 33
Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy 31
Cerebrospinal Fluid Leak Repair: Usefulness of Intrathecal Fluorescein for Correct Topographic Identification of the Skull Base Defects 28
A case of chronic eosinophilic pneumonia in a patient treated with dupilumab 27
Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders 25
Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy 25
Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma 25
Do the current guidelines for asthma pharmacotherapy encourage over-treatment? 25
Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report 25
Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85 24
Quick Olfactory Sniffin’ Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients 23
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 23
Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study 23
Biologics for the Treatments of Allergic Conditions: Severe Asthma 20
Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports 19
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 19
Real-life studies in allergen immunotherapy 18
Severe chronic rhinosinusitis treated with dupilumab, a real-life analysis of early effectiveness 17
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus 17
Personalizing the approach to asthma treatment 17
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life 16
COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy 16
Impulse oscillometry defined small airway dysfunction in asthmatic patients with normal spirometry: Prevalence, clinical associations, and impact on asthma control 16
Specific Therapy for T2 Asthma 14
Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps 14
Diagnostic therapeutic assistance pathway (PDTA) of type 2 chronic rhinosinusitis 14
Real-life studies of biologics used in asthma patients: key differences and similarities to trials 14
Nasal cytology as a reliable non-invasive procedure to phenotype patients with type 2 chronic rhinosinusitis with nasal polyps 12
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 11
Management of Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Shared Approach 11
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 9
Efficacy and steroid-sparing effect of benralizumab: Has it an advantage over its competitors? 9
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses 9
The new indications for biologicals in type 2 diseases: perspectives 8
Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review 8
New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases 7
COVID-19, Eosinophils, and Biologicals for Severe Asthma 6
Small Airways: The “Silent Zone” of 2021 GINA Report? 6
Type 2 immunity in asthma 6
Strategies to reduce corticosteroid-related adverse events in asthma 6
Severe asthma, biologicals, and auto-injection: Yes, no, may be! 6
Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis 5
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 5
Small airway dysfunction and poor asthma control: a dangerous liaison 5
Personalized medicine and allergen immunotherapy: the beginning of a new era? 4
Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85 4
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 4
New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases 4
Strategies to reduce corticosteroid-related adverse events in asthma 4
Totale 5.475
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.563
article - articoli 23.355
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.918
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020951 0 0 0 0 0 160 204 127 142 161 122 35
2020/2021716 31 45 51 58 65 39 38 61 42 91 46 149
2021/2022595 21 11 17 63 15 72 23 130 53 76 14 100
2022/2023874 67 77 8 72 89 127 73 42 153 54 96 16
2023/2024724 42 82 9 82 49 183 43 44 37 14 49 90
2024/2025790 58 137 59 140 219 177 0 0 0 0 0 0
Totale 5.479